Unfractionated Heparin Dosing for NSTEMI
For this 74-year-old man with NSTEMI and elevated troponin, administer unfractionated heparin with an initial IV bolus of 60 units/kg (maximum 4,000 units) followed by continuous infusion of 12 units/kg/hour (maximum 1,000 units/hour), targeting aPTT of 1.5-2 times normal (50-70 seconds). [@1,2,3,9,10@]
Dosing Algorithm
Initial Dosing
The ACC/AHA guidelines provide clear Class I, Level A recommendations for UFH in NSTEMI [@1,2,3,9,10@]:
- Bolus: 60 units/kg IV (maximum 4,000 units)
- Infusion: 12 units/kg/hour (maximum 1,000 units/hour)
- Target aPTT: 50-70 seconds (1.5-2 times control)
The FDA label confirms continuous IV infusion dosing of 20,000-40,000 units/24 hours (833-1,667 units/hour range), with initial 5,000 unit bolus [@13,14,15@]. However, the weight-based guideline dosing is superior and should be used rather than fixed dosing, as fixed dosing leads to excess weight-adjusted doses in 35% of patients, particularly in elderly and lower-weight individuals 1.
Monitoring Protocol
Critical monitoring parameters [@13,14@]:
- Baseline: aPTT, INR, platelet count
- aPTT every 4 hours initially until therapeutic range achieved
- Then aPTT at appropriate intervals (typically every 6-12 hours once stable)
- Platelet counts periodically throughout therapy to detect heparin-induced thrombocytopenia
- Hematocrit and occult blood monitoring
Duration of Therapy
Continue IV UFH for at least 48 hours if medical management is selected [@2,3,10@]. For patients proceeding to PCI, discontinue anticoagulant after uncomplicated PCI [@1,2,3@]. If CABG is planned, continue UFH (do not discontinue) [@1,2,3,4,5@].
Renal Impairment Considerations
Critical Decision Point
Renal function fundamentally changes anticoagulant selection in this patient. The 2014 AHA/ACC and 2020 ESC guidelines provide specific guidance [@11,12@]:
For patients with severe renal impairment (CrCl <30 mL/min):
- UFH is PREFERRED over enoxaparin 2
- Enoxaparin requires dose reduction to 1 mg/kg SC once daily (from twice daily) when CrCl <30 mL/min 2
- Fondaparinux is contraindicated when serum creatinine >3.0 mg/dL 3
UFH advantages in renal impairment:
- Does not require renal dose adjustment [@11,12@]
- Cleared by reticuloendothelial system, not kidneys
- Can be monitored with aPTT
- Reversible with protamine
Bleeding Risk in Renal Dysfunction
Patients with CKD have significantly elevated bleeding risk [@18,20@]:
- CrCl is an independent predictor of major bleeding (OR 1.06 per 10 mL/min decrease) 4
- Severe renal impairment (CrCl <30 mL/min) increases major hemorrhage 6-fold (6.6% vs 1.1%, P<0.0001) 5
- This bleeding risk applies equally to UFH and enoxaparin - no treatment interaction exists 4
Practical Approach
- Calculate CrCl using Cockcroft-Gault equation with ideal body weight 6
- If CrCl ≥30 mL/min: Either UFH (preferred for flexibility) or enoxaparin 1 mg/kg SC q12h acceptable 2
- If CrCl <30 mL/min: Use UFH exclusively - avoid enoxaparin unless dose reduced to once daily and strong clinical justification exists 2
- If serum creatinine >3.0 mg/dL: Absolutely avoid fondaparinux 3
Common Pitfalls
Weight-Based Dosing Errors
The most frequent error is using fixed doses (5,000 unit bolus, 1,000 units/hour infusion) rather than weight-adjusted dosing 1. This results in:
- Overdosing in elderly and low-weight patients (particularly women)
- 35% of patients receive excess weight-adjusted doses
- Proportional increase in major bleeding with doses >70 units/kg bolus or >15 units/kg/hour infusion 1
Renal Function Assessment
Do not rely on serum creatinine alone - elderly patients often have "normal" creatinine despite significant renal impairment [@19,20@]. Calculate CrCl before selecting anticoagulant.
Monitoring Frequency
Inadequate aPTT monitoring is dangerous - check every 4 hours initially, not every 12-24 hours [@13,14@]. Subtherapeutic anticoagulation increases ischemic events; supratherapeutic increases bleeding.
PCI Considerations
If proceeding to PCI after initial UFH treatment [@9,12@]:
- Continue UFH - give additional boluses as needed based on ACT
- Target ACT 250-300 seconds (HemoTec) or 300-350 seconds (Hemochron) if no GP IIb/IIIa inhibitor
- Target ACT 200 seconds if GP IIb/IIIa inhibitor used 7
- Discontinue after uncomplicated PCI [@1,2,3@]
Alternative Anticoagulants in Renal Impairment
The 2020 ESC guidelines note that fondaparinux is recommended when medical treatment is selected and transfer delays exist, but requires UFH bolus (50-60 units/kg) at time of PCI to prevent catheter thrombosis 8. However, this applies only to patients WITHOUT severe renal impairment.